Therapeutics targeting Bcl-2 in hematological malignancies

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The B-cell lymphoma 2 (BCL-2) gene family regulates cell survival, a key cancer hallmark.
• Selective inhibition of anti-apoptotic Bcl-2 proteins, like venetoclax, is FDA-approved for chronic lymphocytic leukemia (CLL).
• Limited efficacy in other B-cell malignancies suggests combination therapies are necessary.

Purpose of the Study:

• To review progress in direct and selective targeting of Bcl-2 family proteins.
• To explore rationale combination therapies for cancer treatment.
• To identify strategies for overcoming venetoclax resistance and expanding clinical utility.

Main Methods:

• Review of preclinical and clinical development of Bcl-2 family protein antagonists.
• Analysis of combination therapy approaches, including gene expression modulation.
• Literature search on BH3 mimetics and their role in cancer therapy.

Main Results:

• Venetoclax demonstrates significant monotherapy activity in CLL with 17p deletion.
• Preclinical data indicate combination therapies are required for broader efficacy.
• Development of additional antagonists (Bcl-X_L, Mcl-1) is ongoing.

Conclusions:

• Direct targeting of Bcl-2 family proteins offers a promising therapeutic avenue.
• Combination therapies are essential to enhance responses and overcome resistance.
• Future strategies may involve down-regulating anti-apoptotic proteins or restoring pro-apoptotic proteins.